Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. The Darmstadt, Germany based enterprise develops small molecule drug candidates. In doing so, the company is working at the cutting edge of drug discovery designing compounds that block dysregulated enzymatic activity of transglutaminases.

Drug candidates developed by Zedira:

 ZED1227  
 Proof-of-concept shown in Phase 2a study in celiac disease
  • All dose groups met the primary endpoint
  • Placebo-like safety profile
  • First-in-class compound
  • Validation of a transglutaminase as druggable target for the first time
 Partnering opportunity:

Licensed to Takeda and Dr. Falk Pharma

 ZED1227 
 
Proof-of-concept shown in Phase 2a study in celiac disease
  • All dose groups met the primary endpoint
  • Placebo-like safety profile
  • First-in-class compound
  • Validation of a transglutaminase as druggable target for the first time
 
 
Partnering opportunity:

Licensed to Takeda and Dr. Falk Pharma

 
  

 ZED3269  
 
  • Novel 2nd generation tissue transglutaminase inhibitor
  • Improved oral bioavailability
  • Reversible-acting warhead
  • Rodent pharmacokinetic and efficacy data available
 Seeking licensee(s) / development partner(s)

Preferred indications include
  • Diabetic nephropathy
  • Idiopathic pulmonary fibrosis
  • Mesothelioma cancer
  • Liver fibrosis
 ZED3269 
 
  • Novel 2nd generation tissue transglutaminase inhibitor
  • Improved oral bioavailability
  • Reversible-acting warhead
  • Rodent pharmacokinetic and efficacy data available
 
 
Seeking licensee(s) / development partner(s)

Preferred indications include
  • Diabetic nephropathy
  • Idiopathic pulmonary fibrosis
  • Mesothelioma cancer
  • Liver fibrosis


 
  

 ZED3197  
 
  • First-in-class “safe” anticoagulant
  • Direct-acting irreversible Factor XIIIa (F13a) inhibitor
  • Proof-of-principle in rabbit model shown
 Seeking licensee(s) / development partner(s)

Preferred indications include
  • Haemodialysis
  • Acute kidney injury
  • Acute lung injury
 ZED3197 
 
  • First-in-class “safe” anticoagulant
  • Direct-acting irreversible Factor XIIIa (F13a) inhibitor
  • Proof-of-principle in rabbit model shown
 
 
Seeking licensee(s) / development partner(s)

Preferred indications include
  • Haemodialysis
  • Acute kidney injury
  • Acute lung injury
 
  

Zedira is open to considering alliances and deals with the pharmaceutical industry. Please do not hesitate to contact us.Zedira’s management team, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal:

Phone:    +49 6151 66628-0 or
E-mail:    contact@zedira.com

News

Blog

Events